about
Effect of latent membrane protein 1 expression on overall survival in Epstein-Barr virus-associated cancers: a literature-based meta-analysisRecommendation for a contouring method and atlas of organs at risk in nasopharyngeal carcinoma patients receiving intensity-modulated radiotherapy.Influence of Cervical Node Necrosis of Different Grades on the Prognosis of Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiotherapy.Socioeconomic factors and survival in patients with non-metastatic head and neck squamous cell carcinoma.Promising treatment outcomes of intensity-modulated radiation therapy for nasopharyngeal carcinoma patients with N0 disease according to the seventh edition of the AJCC staging system.Prognostic value and staging classification of retropharyngeal lymph node metastasis in nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.Comparison of long-term survival and toxicity of cisplatin delivered weekly versus every three weeks concurrently with intensity-modulated radiotherapy in nasopharyngeal carcinomaLow BRMS1 expression promotes nasopharyngeal carcinoma metastasis in vitro and in vivo and is associated with poor patient survivalWhich T category of nasopharyngeal carcinoma may benefit most from volumetric modulated arc therapy compared with step and shoot intensity modulated radiation therapy.The pretreatment albumin to globulin ratio has predictive value for long-term mortality in nasopharyngeal carcinomaIncidence of and Risk Factors for Mastoiditis after Intensity Modulated Radiotherapy in Nasopharyngeal Carcinoma.Clinical Outcomes of Volume-Modulated Arc Therapy in 205 Patients with Nasopharyngeal Carcinoma: An Analysis of Survival and Treatment Toxicities.Investigation of the feasibility of elective irradiation to neck level Ib using intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma: a retrospective analysisIdentification of surrogate endpoints in patients with locoregionally advanced nasopharyngeal carcinoma receiving neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone.Potential surrogate endpoints for overall survival in locoregionally advanced nasopharyngeal carcinoma: an analysis of a phase III randomized trialEfficacy of the Additional Neoadjuvant Chemotherapy to Concurrent Chemoradiotherapy for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: a Bayesian Network Meta-analysis of Randomized Controlled Trials.Neoadjuvant and Concurrent Chemotherapy Have Varied Impacts on the Prognosis of Patients with the Ascending and Descending Types of Nasopharyngeal Carcinoma Treated with Intensity-Modulated RadiotherapyThe Evolution of and Risk Factors for Neck Muscle Atrophy and Weakness in Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy: A Retrospective Study in an Endemic AreaDose-volume factors associated with ear disorders following intensity modulated radiotherapy in nasopharyngeal carcinoma.Neoadjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: Defining high-risk patients who may benefit before concurrent chemotherapy combined with intensity-modulated radiotherapy.Value of the prognostic nutritional index and weight loss in predicting metastasis and long-term mortality in nasopharyngeal carcinomaHepatitis B virus screening and reactivation and management of patients with nasopharyngeal carcinoma: A large-scale, big-data intelligence platform-based analysis from an endemic area.Dose-volume relationships for moderate or severe neck muscle atrophy after intensity-modulated radiotherapy in patients with nasopharyngeal carcinoma.Circulating EBV DNA, Globulin and Nodal Size Predict Distant Metastasis after Intensity-Modulated Radiotherapy in Stage II Nasopharyngeal Carcinoma.Risk stratification based on change in plasma Epstein-Barr virus DNA load after treatment in nasopharyngeal carcinomaEvaluation of sixth edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement.Primary tumor inflammation in gross tumor volume as a prognostic factor for nasopharyngeal carcinoma patientsPrognostic value of wait time in nasopharyngeal carcinoma treated with intensity modulated radiotherapy: a propensity matched analysis.Should All Nasopharyngeal Carcinoma with Paranasal Sinus Invasion Be Staged as T3 in the Intensity-Modulated Radiotherapy Era? A Study of 1811 CasesCigarette smoking complements the prognostic value of baseline plasma Epstein-Barr virus deoxyribonucleic acid in patients with nasopharyngeal carcinoma undergoing intensity-modulated radiation therapy: a large-scale retrospective cohort study.Exploration and Validation of C-Reactive Protein/Albumin Ratio as a Novel Inflammation-Based Prognostic Marker in Nasopharyngeal Carcinoma.Prognostic Value and Grading of MRI-Based T Category in Patients With Nasopharyngeal Carcinoma Without Lymph Node Metastasis Undergoing Intensity-Modulated Radiation Therapy.Locoregional extension patterns of nasopharyngeal carcinoma and suggestions for clinical target volume delineation.Long-term outcome and late toxicities of simultaneous integrated boost-intensity modulated radiotherapy in pediatric and adolescent nasopharyngeal carcinoma.Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapy.MiR-451 inhibits cell growth and invasion by targeting MIF and is associated with survival in nasopharyngeal carcinoma.Re-evaluation of 6th edition of AJCC staging system for nasopharyngeal carcinoma and proposed improvement based on magnetic resonance imaging.Prognostic factors and failure patterns in non-metastatic nasopharyngeal carcinoma after intensity-modulated radiotherapy.Changes in Disease Failure Risk of Nasopharyngeal Carcinoma over Time: Analysis of 749 Patients with Long-Term Follow-Up.Radiotherapy with neoadjuvant chemotherapy versus concurrent chemoradiotherapy for ascending-type nasopharyngeal carcinoma: a retrospective comparison of toxicity and prognosis.
P50
Q26786050-748CF7BB-40AB-4931-8BC9-4BC6827B2831Q30798219-FF4FABD0-5DB7-416B-9901-3398790BF65FQ33702308-79EE0053-AD17-49C4-90BB-A2CB1960D993Q33823208-33DFDB40-CC8A-4048-B3B0-0049870C99C0Q34159567-7DEFA2DD-1606-4486-82D7-A4FFAE938A0BQ34323090-EFA07EBB-18BA-4B97-911D-1D4A6BAC363EQ34352211-2389E516-92B1-4C82-A470-1B6B09C670FFQ34397133-0C722DF1-0D62-4B15-B522-A6E94085A54CQ35005542-914AC7D0-1CAC-4824-AB48-7684AFA83435Q35144019-64DFE882-CF71-42A6-B481-BCB75440C262Q35675444-6C200560-CB3A-4052-A399-81F1F33B18B8Q35683086-EAF5D51A-0F9A-42F7-BB64-5A4A69BB85E7Q35809636-820F0096-0FD4-47AF-A9F0-C41C63A4F35BQ35851730-C1C508E6-EC98-4943-98C1-301FA6D998F8Q35898182-5062E921-66CA-402D-93AE-4DC82C75F52AQ35942191-AAE7F6D1-1644-40FE-9054-86F606E560C4Q36174879-23F0617E-9FC0-4526-AF9B-47159B3D18FAQ36194609-E3F66ADA-67D3-43D5-8429-746C4B44599CQ36273672-6F673C30-66CC-4E5F-9BC2-25EC6ED413E5Q36275495-8DE9E482-1B57-4D8A-921F-EF79C3223F2EQ36301765-4ED69BFE-8B56-4CD7-AAFB-E63A16E0416FQ36368747-14FACB1F-F2DF-4AAE-BB89-C1B5156B1E28Q36382531-380A14DE-4CA8-4A53-93AB-2CDA125A57C7Q36792351-4B969D98-27A4-4EA3-B706-259278F0E0E6Q36962686-D6FFCF21-A457-4E7B-9E23-A55B896B307FQ37013994-5C881FED-90C4-475E-AEC5-290DE27AE62FQ37046765-B8089345-8A0B-4193-974B-CFB07334073DQ37046770-59CFF22E-FE10-4CCB-80E2-D13E0993E506Q37068038-0BD0506C-723A-41C0-889F-FE6E169F84D3Q37086130-E352BFCA-1980-49ED-84CD-4B5F854EDC9DQ37133633-E6796402-466C-4962-A8BB-5D6F2248184FQ37176127-E0C750E8-6AD7-4725-AB59-5E3E88FE11EBQ37183618-43C7F3AD-03F6-4DF8-9C6D-BC0455A4B458Q37353928-031E1472-895A-4B0F-842E-36719E40D383Q37353991-F5F01361-8142-4D8E-96E9-8740423DD346Q37368364-A5A09FBC-69CB-4679-BCEA-90B7DB76F096Q37372141-66811D07-98A1-41F5-AB64-495E95BDADF5Q37539740-038A0E43-0FD2-4415-B708-35BF5D4FDFFEQ37675989-C44B22D2-FE87-4A08-9921-B105EB1B74B7Q37681958-466B2C4C-2FC7-466C-A134-42A6B241EE65
P50
name
Ling-Long Tang
@en
Ling-Long Tang
@nl
type
label
Ling-Long Tang
@en
Ling-Long Tang
@nl
prefLabel
Ling-Long Tang
@en
Ling-Long Tang
@nl